1-(tert-butoxycarbonyl)-4-phenyl-1,2,5,6-tetrahydropyridine-3-carboxylic acid | 170838-40-1

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: 1-(tert-butoxycarbonyl)-4-phenyl-1,2,5,6-tetrahydropyridine-3-carboxylic acid
• 英文别名: 1-(t-butoxycarbonyl)-4-phenyl-1,2,5,6-tetrahydronicotinic acid；4-phenyl-5,6-dihydro-2H-pyridine-1,3-dicarboxylic acid 1-tert-butyl ester；1-(tert-Butoxycarbonyl)-4-phenyl-1,2,5,6-tetrahydropyridin-3-carboxylic acid；1-[(2-methylpropan-2-yl)oxycarbonyl]-4-phenyl-3,6-dihydro-2H-pyridine-5-carboxylic acid
• CAS: 170838-40-1
• 化学式: C₁₇H₂₁NO₄
• 分子量: 303.358
• InChiKey: DVHUSCHKHCBZKT-UHFFFAOYSA-N

物化性质

• 沸点：
  435.6±45.0 °C(Predicted)
• 密度：
  1.211±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  66.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-(tert-butoxycarbonyl)-4-phenyl-1,2,5,6-tetrahydropyridine-3-carboxylic acid 在 palladium-carbon 氢气 作用下， 以 甲醇 为溶剂， 反应 2.0h， 以to give the title compound (4.76 g)的产率得到(3S,4S)-cis-N-(tert-butoxycarbonyl)-4-phenyl-3-carboxypiperidine
  参考文献：
  名称：

  BICYCLIC HETEROCYCLIC DERIVATIVE

  摘要：

  本发明涉及以下式（I）的化合物或其药学上可接受的盐，其可用作肾素抑制剂。[其中，R1a是卤素等；R1m是H等；G1是—N（R1b）—等；G2是—CO—等；G3是—C（R1c）（R1d）—等；G4是氧等；R1b是可选取代的C1-6烷基等；R1c和R1d独立选择为H等；R3是H、可选取代的C1-6烷基等；R3a、R3b、R3c和R3d独立选择为相同或不同的基团：-A-B（其中A是单键等，B是H等）等；n为1等。]

  公开号：

  US20110190278A1
• 作为产物：
  描述：

  1-N-Boc-4-氧代-3-哌啶羧酸乙酯 在 四(三苯基膦)钯 、 sodium carbonate 、 二异丙胺 、 potassium hydroxide 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 、 水 为溶剂， 反应 5.5h， 生成 1-(tert-butoxycarbonyl)-4-phenyl-1,2,5,6-tetrahydropyridine-3-carboxylic acid
  参考文献：
  名称：

  Structural Modifications to Tetrahydropyridine-3-carboxylate Esters en Route to the Discovery of M₅-Preferring Muscarinic Receptor Orthosteric Antagonists

  摘要：

  The M-5 muscarinic acetylcholine receptor is suggested to be a potential pharmacotherapeutic target for the treatment of drug abuse. We describe herein the discovery of a series of M-5-preferring orthosteric antagonists based on the scaffold of 1,2,5,6-tetrahydropyridine-3-carboxylic acid. Compound 56, the most selective compound in this series, possesses an 11-fold selectivity for the M-5 over M-1 receptor and shows little activity at M-2-M-4. This compound, although exhibiting modest affinity (K-i = 2.24 mu M) for the [H-3]N-methylscopolamine binding site on the M-5 receptor, is potent (IC50 = 0.45 nM) in inhibiting oxotremorine-evoked [H-3]DA release from rat striatal slices. Further, a homology model of human M-5 receptor based on the crystal structure of the rat M-3 receptor was constructed, and docking studies of compounds 28 and 56 were performed in an attempt to understand the possible binding mode of these novel analogues to the receptor.

  DOI：

  10.1021/jm301774u

文献信息

• NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND
  申请人：SUMITOMO CHEMICAL COMPANY, LIMITED

  公开号：US20160221948A1

  公开（公告）日：2016-08-04

  The present invention provides a compound represented by the following formula (I) or its pharmaceutically acceptable salt: [wherein, R 1 represents optionally substituted C 1-4 alkyl, n shows integer of 1 to 4, R 2 represents optionally substituted C 1-4 alkyl or hydrogen atom, R 3 represents optionally substituted C 1-4 alkyl, R 4a , R 4b , R 4c , and R 4d , similarly or differently, represent optionally substituted C 6-14 aryl, optionally substituted C 1-4 alkyl, or hydrogen atom and the like, A represents optionally substituted C 6-14 aryl or optionally substituted 5 to 11 membered heteroaryl].

  本发明提供了一种由下式(I)表示的化合物或其药用可接受的盐： [其中，R1表示可选地取代的C1-4烷基，n表示1到4的整数，R2表示可选地取代的C1-4烷基或氢原子，R3表示可选地取代的C1-4烷基，R4a、R4b、R4c和R4d，相同或不同，表示可选地取代的C6-14芳基，可选地取代的C1-4烷基，或氢原子等，A表示可选地取代的C6-14芳基或可选地取代的5至11成员的杂芳基]。
• 氧杂螺环双膦配体及其在α,β-不饱和羧酸不 对称氢化中的应用
  申请人：凯特立斯（深圳）科技有限公司

  公开号：CN109503659B

  公开（公告）日：2021-06-18

  本发明提供的一种氧杂螺环双磷配体，具有以下通式(I)的结构：其中，通式(I)中：R1、R2、R3和R4相同，其为烷基、烷氧基、芳基、芳氧基或氢原子，所述R1、R2、R3和R4包括成环、不成环、任意两个成环或两两之间形成多环的形式；R5、R6为烷基、芳基或氢原子；R7、R8为烷基或苄基者芳基。本发明还提供了一种氧杂螺环双膦配体O‑SDP在α,β‑不饱和羧酸不对称氢化中的应用。其与钌的络合物在多种类型的α,β‑不饱和羧酸的不对称氢化中都表现出优异的活性和对映选择性，能够以高达99％的对映选择性得到手性羧酸产物。该合成方法可以应用与Paroxetine、Femoxetine、nipecotic acid以及Sacubitril等具有重要生物活性的化学分子的核心骨架的构建中。
• OXA-SPIRODIPHOSPHINE LIGAND AND METHOD FOR ASYMMETRIC HYDROGENATION OF alpha, beta-UNSATURATED CARBOXYLIC ACIDS
  申请人：SHENZHEN CATALYS TECHNOLOGY CO., LTD.

  公开号：US20210340168A1

  公开（公告）日：2021-11-04

  The present invention provides an oxa-spirodiphosphine ligand having a structure of general Formula (I) below: wherein in general Formula (I), R 1 , R 2 , R 3 and R 4 are the same, and are alkyl, alkoxy, aryl, aryloxy, or hydrogen, in which R 1 , R 2 , R 3 and R 4 may or may not form a ring, any two of them may form a ring, or a polycyclic ring may be formed between two pairs of them; R 5 and R 6 is alkyl, aryl, or hydrogen; and R 7 and R 8 is alkyl, benzyl, or aryl. The present invention also provides a method for asymmetric hydrogenation of α,β-unsaturated carboxylic acids. A complex of the oxa-spirodiphosphine ligand with ruthenium shows excellent activity and enantioselectivity in the asymmetric hydrogenation of various α,β-unsaturated carboxylic acids, with which a chiral carboxylic acid product can be obtained with an enantioselectivity up to 99%.

  本发明提供了一种具有下面一般式（I）结构的氧杂螺环二膦配体： 在一般式（I）中，R1、R2、R3和R4相同，可以是烷基、烷氧基、芳基、芳氧基或氢，其中R1、R2、R3和R4可能形成环，也可能不形成环，其中任意两个可以形成环，或者两对它们之间可能形成多环环；R5和R6是烷基、芳基或氢；R7和R8是烷基、苄基或芳基。本发明还提供了一种不对称氢化α，β-不饱和羧酸的方法。氧杂螺环二膦配体与钌形成的配合物在各种α，β-不饱和羧酸的不对称氢化中表现出优异的活性和对映选择性，可获得对映选择性高达99%的手性羧酸产品。
• Serotonin transporter (sert) inhibitors for the treatment of depression and anxiety
  申请人：Grundschober Christophe

  公开号：US20070232652A1

  公开（公告）日：2007-10-04

  The present invention relates to trans-derivatives of formula wherein R 1 , R 2 , R 3 , and the dotted line are as defined herein and to pharmaceutically acceptable acid addition salts thereof. The compounds of formula I are good inhibitors of the serotonin transporter (SERT inhibitors) and simultaneously, they have good activity on the NK-1 receptor (dual effect). By virtue of their efficacy as SERT inhibitors, the compounds in the present invention are particularly useful for the treatment of CNS disorders and psychotic disorders, in particular in the treatment or prevention of depressive states and/or in the treatment of anxiety.

  本发明涉及公式中的转衍生物，其中R1、R2、R3和虚线如本文所定义，并且其药用可接受酸盐。公式I的化合物是良好的5-羟色胺转运体抑制剂（SERT抑制剂），同时它们对NK-1受体也具有良好的活性（双重效应）。由于其作为SERT抑制剂的功效，本发明中的化合物特别适用于治疗中枢神经系统疾病和精神疾病，特别是在治疗或预防抑郁状态和/或焦虑症的治疗中。
• Process for the preparation of enantiomerically enriched cyclic beta-aryl or heteroaryl carbocyclic acids
  申请人：Bachmann Stephan

  公开号：US20070232653A1

  公开（公告）日：2007-10-04

  The present invention relates to a process for the preparation of cis substituted cyclic β-aryl or heteroaryl carboxylic acid derivatives in high diastereo- and enantioselectivity by enantioselective hydrogenation in accordance with the following scheme wherein X, Ar, n, and m are defined herein and corresponding salts thereof.

  本发明涉及一种通过对下列方案进行对映选择性氢化反应，制备高对映异构体和对映选择性的顺式取代的环状β-芳基或杂芳基羧酸衍生物的方法，其中X、Ar、n和m在此定义，并且包括相应的盐。